Immunome (IMNM) recently dosed the first patient in a Phase 1, first in human trial of IM-1617. This is an antibody drug conjugate for advanced solid tumors that uses the company’s proprietary TOP1 inhibitor payload.

For Immunome, the IM-1617 trial update arrives after a mixed period for the stock, with the share price down 18.38% over the past 30 days but a very strong 114.17% total shareholder return over the last year. This hints that long term momentum has been positive even as some recent enthusiasm has cooled.

If this kind of early stage oncology work interests you, it can be useful to scan a wider set of healthcare AI opportunities through the 40 healthcare AI stocks

With Immunome shares down 18.38% over the past month but showing a very large 3-year total return and trading at a discount to analyst targets and intrinsic estimates, is there still a buying opportunity here, or is the market already pricing in future growth?

Immunome valuation: what the DCF is implying

On Simply Wall St's numbers, Immunome is described as trading below an estimated future cash flow value of $153.32, compared with the recent $18.74 close. That is a very wide gap, so it is worth understanding what the SWS DCF model is actually doing here.

The DCF approach projects a stream of future cash flows for a company and then discounts those back to today using a chosen rate, so that distant cash flows count for less than near term ones. For an early stage oncology business like Immunome, with $4 million of revenue and a reported net loss of $224.593 million, the model is leaning heavily on long run assumptions about how those cash flows might evolve.

That context matters because Immunome is currently unprofitable, is forecast to remain loss making over the next three years, and does not yet have what the framework calls meaningful revenue. In sectors like biotechnology, this kind of disconnect between present financials and a high DCF estimate often reflects expectations around a pipeline of assets, potential approvals and eventual monetisation that sit well beyond the near term earnings horizon.

Result: DCF Fair value of $153.32 (UNDERVALUED)

However, the Immunome story still carries clear risks, including ongoing losses of $224.593 million and heavy reliance on early stage clinical assets like IM-1617 and IM-1021.

Another view on Immunome using market multiples

While the SWS DCF model suggests Immunome could be trading at a steep discount to an estimated future cash flow value, the picture looks more measured when you look at how the market is pricing the stock on a P/B basis.

Immunome’s P/B ratio of 3.6x is described as good value against a peer average of 11x, yet it is also described as expensive versus the wider US biotechs industry at 2.5x. That split hints at both potential opportunity and clear valuation risk, so which side of the comparison matters more for you as an investor?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Immunome for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of enthusiasm and caution around Immunome, it makes sense to look at the underlying data yourself and decide how comfortable you are with both sides of the story before sentiment shifts again. To get a balanced view of the upside and the downsides being flagged by investors, take a moment to review the 3 key rewards and 4 important warning signs

Looking for more investment ideas beyond Immunome?

If you are serious about building a stronger portfolio alongside Immunome, it is worth broadening your research now so you are not chasing opportunities later.

• Target potential value opportunities by scanning the market for companies that look mispriced on fundamentals through the 45 high quality undervalued stocks.
• Strengthen your income stream by focusing on dependable payers using the 8 dividend fortresses.
• Prioritise resilience by focusing on companies with healthier finances via the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.